Prevention of Recurrent Episodes of Depression With Venlafaxine ER in a 1-Year Maintenance Phase From the PREVENT Study

Efficacy and tolerability of extended release quetiapine fumarate monotherapy as maintenance treatment of major depressive disorder: a randomized, placebo-controlled trial

“…In an olanzapine/fluoxetine combination study, improvements in MADRS and CGI-S scores were maintained, [36] whereas in a venlafaxine study, improvements in HAM-A and CGI-S scores were maintained. [37] During the open-label stabilization phase, the most common reason for discontinuation was an AE, and the most common AEs leading to discontinuation (including somnolence, sedation, and fatigue) ( Table 4) were consistent with those observed during short-term monotherapy studies. [13][14][15] The most common AEs during the open-label phase (including somnolence, dry mouth, sedation, and fatigue) were more frequently reported during the first week of treatment.…”

Relapse rates with long‐term antidepressant drug therapy: a meta‐analysis

“…Studies used the same drug in the acute phase and continuation phase with the exception of three (Kocsis et al, 2007;Kornstein et al, 2006;Lepine et al, 2004).…”

“…Otherwise, the rates were extracted from the survival graph figures in the original reports. All of the studies satisfied the 24 week time point, 9 out of 11 studies satisfied the 48 week time point (Gilaberte et al, 2001;Hochstrasser et al, 2001;Keller et al, 1998;Klysner et al, 2002;Kocsis et al, 2007;Kornstein et al, 2006;Lepine et al, 2004;McGrath et al, 2006;Perahia et al, 2006;Reynolds et al, 1999;Sackeim et al, 2001), 4 out of 11 studies satisfied the 72 week time point (Hochstrasser et al, 2001;Keller et al, 1998;Lepine et al, 2004;Reynolds et al, 1999) and only 1 study satisfied the 96 week time point (Reynolds et al, 1999) (Figure 1). …”

“…For instance, we could not test for the potentially critical role attributed to the level of treatment resistance prior to response to a particular intervention and subsequent assignment to a maintenance protocol. Three out of the 11 studies specifically excluded TRD (Gilaberte et al, 2001;Kocsis et al, 2007;Perahia et al, 2006). Only one study reported the Antidepressant History Form (ATHF) values (Sackeim et al, 2001), whereas six of the seven remaining studies had no criteria pertaining to TRD (Hochstrasser et al, 2001;Keller et al, 1998;Klysner et al, 2002;Kornstein et al, 2006;Lepine et al, 2004;McGrath et al, 2006;Reynolds et al, 1999).…”

Desvenlafaxine for the Prevention of Relapse in Major Depressive Disorder

“…The need for the continuation-phase antidepressant treatment is widely recognized; a number of consensus groups in the United States and Europe have recommended that patients should continue to take antidepressants for 4 to 6 months to prevent relapse after a successful acute-phase therapy. 4,5,9,10 Studies with the serotonin-norepinephrine reuptake inhibitor (SNRI) venlafaxine (immediate or extended release [IR or ER]) have demonstrated its efficacy in preventing relapse during up to 12 months of continuation-phase treatment 11,12 and its efficacy in preventing recurrence 13,14 during 1 to 2 years 15 of maintenance treatment in patients who sustained their response for the continuation treatment period. Desvenlafaxine (administered as desvenlafaxine succinate) is the major active metabolite of venlafaxine 16,17 and an SNRI antidepressant.…”